Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead accused of ripping off US taxpayers

March 28, 2019
Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …

News

Japanese court orders public health campaigner to pay ¥3.3 million to anti-vaccine researcher

March 27, 2019
Medical Communications, Research and Development HPV, Japan, anti vaxx, anti-vaccine, public health, vaccines

Dr Riko Muranaka, a researcher and journalist who has campaigned against misinformation surrounding vaccines, has been ordered to pay ¥3.3 …

News
vaccination_2

Measles outbreak spurs New York County to ban all unvaccinated children from public spaces

March 27, 2019
Research and Development New York, US, pharma, vaccination, vaccines

Rockland County, New York State, is taking serious measures to combat its biggest measles outbreak in decades, making the decision …

News
abbvie_0

Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications

March 27, 2019
Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis

AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …

News

Children with high adherence to ADHD medication methylphenidate at greater risk of being prescribed antidepressants

March 27, 2019
Research and Development ADHA, mental health, methylphenidate, mph, psychiatric disorders

Children who were treated with methylphenidate-based medications (i.e. Ritalin) for conditions such as ADHD were at significantly greater risk of …

News
novartis_side_building

Novartis’ new MS drug to cost $88,000 a year

March 27, 2019
Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …

News
920x920

Purdue Pharma settle Oklahoma lawsuit for $270 million

March 26, 2019
Research and Development Oklahoma, OxyContin, Purdue Pharma, opioid crisis, oxycodone

OxyContin drugmaker Purdue Pharma has agreed to pay nearly $270 million to the state of Oklahoma, in order to settle …

News
novo_nordisk_flag

Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes

March 26, 2019
Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …

News
peanuts02-lg

Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data

March 26, 2019
Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma

Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …

News

Sackler Trust halts donations in UK

March 26, 2019
Manufacturing and Production Sackler Trust, arts, culture, donations, funding, gallery, sackler

The Sackler Trust has announced it is suspending all new donations in the UK amid negative publicity linking the family’s …

News

Sanofi may airlift flu vaccines into UK after Brexit

March 26, 2019
Manufacturing and Production EU, France, Sanofi, UK, brexit, channel tunnel, vaccines

French firm Sanofi would airlift flu vaccines into the UK in the case of a highly disruptive exit from the …

News

Google accused of profiting from misleading dementia supplement ads

March 26, 2019
Manufacturing and Production Alzheimer's, dementia, google, pseudomedicine, search engines, tech

Google has been accused of profiting from false hope after running adverts for unproven dementia treatments which can cost as …

News
screen_shot_2019-02-19_at_14

Conducting internal investigations within a pharmaceutical business

March 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Reed Smith, feature, internal investigations, pharma

Though often necessary, internal investigations are seldom smooth or easy. Rosanne Kay, Partner at law firm Reed Smith, outlines a …

Feature
fda2outsideweb

Sanofi and Lexicon’s Zynquista denied type 1 diabetes approval by FDA complete response letter

March 25, 2019
Sales and Marketing Zynquista. FDA, diabetes, pharma

Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type …

News
takeda_usa_pharmaceuticals_u

NICE recommend Takeda’s lymphoma treatment Adcetris

March 25, 2019
Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …

News
cannabis-2152604_960_720

Africa’s legal cannabis market could generate $7.1 billion each year by 2023

March 25, 2019
Sales and Marketing Africa, UN, cannabis, medicnial cannabis, prohibition partners

Africa’s legal cannabis market could generate more than $7.1 billion each year by 2023, according to a report from market …

News
astrazeneca_building_white

AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients

March 25, 2019
Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma

AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …

News
natural-homeopathic-remedy-alternative-homeopathy-1604071

Advertising Standards Authority tells therapists to stop marketing ‘autism cure’

March 25, 2019
Sales and Marketing ASA, CEASE therapy, advertising standards authority, anti-vaccines, autism, vaccines

The Advertising Standards Authority (ASA) has told British therapists to stop marketing a sham ‘cure’ for autism. The regulator told …

News
jazz_pharma

FDA authorises Jazz Pharma’s sleep disorder therapy Sunosi

March 22, 2019
Medical Communications, Sales and Marketing FDA, jazz pharmaceuticals, pharma, sleep apnoea

Jazz Pharmaceuticals has announced that its dopamine and norepinephrine reuptake inhibitor (DNRI) Sunosi (solriamfetol) has been approved by the FDA …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz

This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026